Published in Cancer Biol Ther on August 16, 2012
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol (2014) 0.88
Development of the rat model of lapatinib-induced diarrhoea. Scientifica (Cairo) (2014) 0.75
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol (2009) 4.69
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther (2001) 4.37
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res (2007) 3.18
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther (2008) 1.90
Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal (2006) 1.82
Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol (2009) 1.79
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist (2008) 1.49
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist (2004) 1.42
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res (2009) 1.18
Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer (2006) 1.16
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat (2008) 1.15
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01
Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell (2004) 0.99
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther (2007) 0.93
Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol (R Coll Radiol) (1994) 0.90
Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88
Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol (1998) 0.87
Prevention and management of major side effects of targeted agents in breast cancer. Crit Rev Oncol Hematol (2011) 0.87
Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. Neurotoxicology (2007) 0.86
The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clin Cancer Res (2007) 0.85
Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats. J Med Assoc Thai (2009) 0.85
Involvement of substance P in peripheral neuropathy induced by paclitaxel but not oxaliplatin. J Pharmacol Exp Ther (2011) 0.85
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer (2006) 0.82
Role of granulocyte colony-stimulating factor in paclitaxel-induced intestinal barrier breakdown and bacterial translocation in rats. Chin Med J (Engl) (2011) 0.81
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther (2007) 0.80
Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function. Acta Physiol (Oxf) (2008) 0.80
Long-term exposure of E-mu-Pim1 transgenic mice to 898.4 MHz microwaves does not increase lymphoma incidence. Radiat Res (2002) 4.16
Does research into sensitive areas do harm? Experiences of research participation after a child's diagnosis with Ewing's sarcoma. Med J Aust (2002) 2.27
Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24
Is child sexual abuse declining? Evidence from a population-based survey of men and women in Australia. Child Abuse Negl (2003) 2.23
Animal models of mucositis: implications for therapy. J Support Oncol (2011) 2.13
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
Survivorship care after breast cancer treatment--experiences and preferences of Australian women. Breast (2011) 1.43
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer (2012) 1.27
Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer (2006) 1.16
Patient barriers to optimal cancer pain control. Psychooncology (2003) 1.14
Hormone replacement therapy: to use or not to use? Med J Aust (2003) 1.12
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10
Randomised controlled trial of a service brokerage intervention for ex-prisoners in Australia. Contemp Clin Trials (2013) 1.09
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer (2009) 1.01
Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther (2010) 0.99
Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci (2002) 0.99
Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res (2014) 0.98
Survivorship care after breast cancer: follow-up practices of Australian health professionals and attitudes to a survivorship care plan. Asia Pac J Clin Oncol (2010) 0.97
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
Improving diet, physical activity and other lifestyle behaviours using computer-tailored advice in general practice: a randomised controlled trial. Int J Behav Nutr Phys Act (2012) 0.96
A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther (2007) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Public views on food addiction and obesity: implications for policy and treatment. PLoS One (2013) 0.95
Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab (2009) 0.93
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther (2007) 0.93
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer (2013) 0.93
Chemotherapy-induced diarrhoea. Curr Opin Support Palliat Care (2009) 0.93
Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer (2014) 0.92
Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys (2005) 0.92
Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer (2014) 0.92
Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol (2009) 0.91
A randomized controlled trial of a standardized educational intervention for patients with cancer pain. J Pain Symptom Manage (2010) 0.89
Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) (2007) 0.89
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer (2014) 0.89
Essential developmental, genomic stability, and tumour suppressor functions of the mouse orthologue of hSSB1/NABP2. PLoS Genet (2013) 0.87
Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) (2010) 0.85
Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy (2007) 0.85
Validation of the English version of the Trust in Oncologist Scale (TiOS). Patient Educ Couns (2012) 0.85
Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer (2007) 0.85
Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis. Support Care Cancer (2014) 0.85
Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model. J Neurooncol (2007) 0.84
The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol (2002) 0.84
Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors. Exp Biol Med (Maywood) (2013) 0.84
Supportive care needs and preferences of lung cancer patients: a semi-structured qualitative interview study. Support Care Cancer (2014) 0.83
ask for it: development of a health advocacy intervention for adults with intellectual disability and their general practitioners. Health Promot Int (2004) 0.83
Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer. ANZ J Surg (2015) 0.82
A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers. Melanoma Res (2014) 0.82
Mucositis guidelines: what have they achieved, and where to from here? Support Care Cancer (2006) 0.82
Predictors of acute adverse events from rapid rituximab infusion. Support Care Cancer (2013) 0.81
The biologic response to particles from a lumbar disc prosthesis. Spine (Phila Pa 1976) (2002) 0.81
Sexual abuse in childhood and physical and mental health in adulthood: an Australian population study. Arch Sex Behav (2007) 0.81
Design and baseline characteristics of the 10 Small Steps Study: a randomised controlled trial of an intervention to promote healthy behaviour using a lifestyle score and personalised feedback. BMC Public Health (2012) 0.80
Role of p53 in irinotecan-induced intestinal cell death and mucosal damage. Anticancer Drugs (2007) 0.80
Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol (2006) 0.80
Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther (2007) 0.80
Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Res (2013) 0.80
Developing an evidence-based clinical pathway for the assessment, diagnosis and management of acute Charcot Neuro-Arthropathy: a systematic review. J Foot Ankle Res (2013) 0.79
Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. Nutrients (2013) 0.79
Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration. J Neurotrauma (2004) 0.79
Health and social correlates of Internet use for diabetes information: findings from Australia's Living with Diabetes Study. Aust J Prim Health (2015) 0.79
Health-related quality of life and congenital heart disease in Australia. J Paediatr Child Health (2013) 0.79
Is simulation training effective in increasing podiatrists' confidence in foot ulcer management? J Foot Ankle Res (2011) 0.79
Sexual dysfunction in the Australian population. Aust Fam Physician (2003) 0.79
Technological advances in mucositis research: new insights and new issues. Cancer Treat Rev (2008) 0.78
Randomized controlled trial of a computer-tailored multiple health behaviour intervention in general practice: 12-month follow-up results. Int J Behav Nutr Phys Act (2014) 0.78
What are the pertinent quality-of-life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire. Melanoma Res (2013) 0.78
Mobile telephones and brain vascular leakage. Pathology (2004) 0.78
Novel therapies. Semin Oncol Nurs (2004) 0.78
Prevalence and risk factors for lifetime exposure to Pap smear abnormalities in the Australian community. Sex Health (2006) 0.77
Dietary omega-3 supplementation exacerbates left ventricular dysfunction in an ovine model of anthracycline-induced cardiotoxicity. J Card Fail (2012) 0.77
Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. Chemotherapy (2011) 0.77
Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol (2007) 0.77
New pathways for alimentary mucositis. J Oncol (2008) 0.77
Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemother Pharmacol (2014) 0.76
Decisions about neoadjuvant systemic therapy for breast cancer: a survey of Australian and New Zealand specialists. ANZ J Surg (2015) 0.76